Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this year.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Moderna beats loss estimates, revenue expectationsCopy link to sectionIn the first quarter, Moderna recorded a net loss of $1.175 billion, or $3.07 per share, which was less than the anticipated loss of ...

Moderna on Thursday posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine, its only commercially available product, topped estimates. The results come as Moderna inches closer to putting another product on the market, which it badly needs as demand for Covid shots plunges worldwide. The biotech company expects a U.S. approval for its vaccine against respiratory syncytial virus on May 12. If cleared, that shot is expected to ...

Exhibit 99.1 Initiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinoma Advanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor event CAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported f ...

USA News Group Commentary Issued on behalf of BioVaxys Technology Corp. VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-kno ...

Moderna (MRNA) will report first-quarter 2024 results on May 2, before the opening bell. In the last reported quarter, the company reported an earnings surprise of 170.51%.Factors to NoteThe Zacks Consensus Estimate for Moderna’s total revenues is pegged at around $125 million, while the same for earnings stands at a loss of $3.59 per share. Both metrics indicate significant declines from the year-ago quarter’s levels.During the first quarter, sales of COVID-19 vaccines are likely to have declined due to lo ...

Moderna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 1.02%. Elsewhere, the Dow gained 0.4%, while the tech-heavy Nasdaq added 2.03%.Heading into today, shares of the biotechnology company had lost 0.36% over the past month, outpacing the Medical sector's loss of 5.2% and the S&P 500's loss of 3.15% in that time.Analysts and investors alike will be keeping a close eye on the performa ...

This ambitious biotech aims to launch 15 products over the coming five years.Moderna (MRNA -2.45%) stock soared earlier in the pandemic as the company developed its coronavirus vaccine and the product went on to generate billions of dollars in sales. But as demand for the vaccine declined, Moderna stock followed. Investors are worried about future growth since the vaccine is the biotech's only commercialized product.But things may be about to turn around for Moderna. The biotech company aims to bring as man ...

Moderna (MRNA) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this biotechnology company have returned -0.4%, compared to the Zacks S&P 500 composite's -0.9% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Moderna falls in, has lost 7.5%. The key question now is: What could be the stock's future direction?While med ...

Moderna (MRNA) closed the most recent trading day at $107.01, moving -0.12% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.74%. At the same time, the Dow lost 0.01%, and the tech-heavy Nasdaq gained 1.68%.Prior to today's trading, shares of the biotechnology company had gained 0.59% over the past month. This has outpaced the Medical sector's loss of 4.72% and lagged the S&P 500's gain of 0.8% in that time.The investment community will be paying close atte ...

Moderna on Thursday said it has paused plans to build a vaccine manufacturing site in Kenya after a steep drop in demand for its Covid vaccines.The biotech company said it has not received any vaccine orders for Africa since 2022 and has taken more than $1 billion in losses and write-downs related to the cancellation of previous orders from the continent.Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine manufacturing footprint. The company's business took a major h ...